Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aura Biosciences (AURA) Total Non-Current Liabilities (2020 - 2022)

Aura Biosciences filings provide 3 years of Total Non-Current Liabilities readings, the most recent being $5.9 million for Q2 2022.

  • Quarterly Total Non-Current Liabilities changed N/A to $5.9 million in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $5.9 million through Jun 2022, changed N/A year-over-year, with the annual reading at $7.6 million for FY2021, 185.95% up from the prior year.
  • Total Non-Current Liabilities hit $5.9 million in Q2 2022 for Aura Biosciences, up from $5.2 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $7.6 million in Q4 2021 and bottomed at $2.7 million in Q4 2020.
  • Average Total Non-Current Liabilities over 3 years is $5.5 million, with a median of $5.9 million recorded in 2022.
  • Peak annual rise in Total Non-Current Liabilities hit 185.95% in 2021, while the deepest fall reached 185.95% in 2021.
  • Aura Biosciences' Total Non-Current Liabilities stood at $2.7 million in 2020, then soared by 185.95% to $7.6 million in 2021, then dropped by 23.18% to $5.9 million in 2022.
  • Per Business Quant, the three most recent readings for AURA's Total Non-Current Liabilities are $5.9 million (Q2 2022), $5.2 million (Q1 2022), and $7.6 million (Q4 2021).